In this study, we found that tDCS administration significantly reduced the level of pro-inflammatory cytokines (i.e. IL-1β, IL-6 and TNF-α) and increased the level of anti-inflammatory factor (i.e. IL-10) in the CIP, which was consistent with previous study [38]. The gene discussed is IL1B; the disease is hereditary sensory and autonomic neuropathy.